Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL17435946

CCCC[N+](CCCC)(CCCC)CCCC.O=S(=O)(F)NS(=O)(=O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.49
SLC22A1 O15245 3/20 0.43
SLC22A2 O15244 1/20 0.38
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
ALOX12 P18054 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
HSD17B10 Q99714 1/20 0.35
FAAH O00519 3/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CES1 P23141 2/20 0.34
CES2 O00748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL31550869 0.91 EPHX1 (0.53) EPHX1SLC22A1SLC22A2ALDH1A1TP53
Tetrabuthylammonium SCHEMBL17435894 0.90 EPHX1 (0.42) EPHX1SLC22A1SLC22A2ALDH1A1TP53
SCHEMBL302116 0.87 EPHX1 (0.55) EPHX1SLC22A1SLC22A2ALDH1A1TP53
SCHEMBL303834 0.87 EPHX1 (0.55) EPHX1SLC22A1SLC22A2ALDH1A1TP53
SCHEMBL302081 0.87 EPHX1 (0.55) EPHX1SLC22A1SLC22A2ALDH1A1TP53
Tetrabuthylammonium SCHEMBL17435902 0.85 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrylammonium SCHEMBL17435864 0.81 CA1 (0.39) EPHX1TSHRSMN1; SMN2CA1CA2
Tetrabuthylammonium SCHEMBL160606 0.79 SLC22A1 (0.52) EPHX1SLC22A1SLC22A2ALDH1A1TP53
Dodecane SCHEMBL30193423 0.78 EPHX1 (0.67) EPHX1HSD17B10FAAHCES1CES2
Nonane SCHEMBL30193525 0.78 EPHX1 (0.67) EPHX1HSD17B10FAAHCES1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109803952-B Sulfamic acid derivatives and process for preparing same 魁北克电力公司 2022-10-04 CN disclosed
US-11345657-B2 Sulfamic acid derivatives and processes for their preparation HYDRO-QUEBEC (CA) 2022-05-31 US disclosed
US-20200181071-A1 SULFAMIC ACID DERIVATIVES AND PROCESSES FOR THEIR PREPARATION HYDRO-QUéBEC (CA) 2020-06-11 US disclosed
US-9950929-B2 Method for producing disulfonylamine alkali metal salt NIPPON SODA CO., LTD. (JP) 2018-04-24 US disclosed
EP-2977349-A1 METHOD FOR PRODUCING DISULFONYLAMINE ALKALI METAL SALT Nippon Soda Co., Ltd. (JP) 2016-01-27 EP disclosed
US-20160016797-A1 METHOD FOR PRODUCING DISULFONYLAMINE ALKALI METAL SALT NIPPON SODA CO., LTD. (JP) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345657-B2 Sulfamic acid derivatives and processes for their preparation STS, SCLY, MPST EPHX1 3891/4885SLC22A1 2718/4885SLC22A2 2716/4885
US-20200181071-A1 SULFAMIC ACID DERIVATIVES AND PROCESSES FOR THEIR PREPARATION STS, SCLY, MPST EPHX1 3891/4885SLC22A1 2718/4885SLC22A2 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.